Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi. The pathogenic microbes can spread, directly or indirectly, from one person to another. Some of the common infectious diseases include pneumonia, HIV/AIDS, malaria, sepsis, hepatitis A-E and tuberculosis. Infectious disease therapeutics are drugs and biological products used to treat or prevent infectious diseases. The major classes of therapeutics include anti-infectives such as antibacterial, antiviral and antifungal drugs. The increasing incidence of infectious diseases globally is driving the need for innovative and effective infectious disease therapeutics.
The infectious disease therapeutics market is estimated to be valued at US$ 170.67 Bn in 2023 and is expected to exhibit a CAGR of 3.7% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the infectious disease therapeutics market is the rising focus on R&D for novel therapeutic approaches and strategies. With the emergence of new pathogens and resistance to existing therapies, drug developers are exploring new mechanisms of action, therapeutic classes, and platforms such as monoclonal antibodies, molecularly targeted therapies, gene therapies and vaccines. Nanomedicine is also emerging as a promising field for development of new infectious disease therapeutics. Nanoparticles can be engineered to selectively target pathogens, reduce toxicity and improve drug formulations. Another trend is the growing collaboration between industry and academic organizations for infectious disease drug development. Open innovation models and precompetitive partnerships are expediting research and helping address the global challenge of antimicrobial resistance.
Threat of new entrants: The biopharmaceutical industry requires large R&D investments and regulatory approvals which act as entry barriers for new players.
Bargaining power of buyers: The bargaining power of buyers is moderate as the need for infectious disease therapeutics is inelastic in nature.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the specialized nature of raw materials required by the biopharmaceutical companies.
Threat of new substitutes: Threat of new substitutes is low as developing new drug molecules require huge investments and time.
Competitive rivalry: The global infectious disease therapeutics market is highly competitive with presence of large multinational companies.
The global infectious disease therapeutics market size is expected to witness high growth, exhibiting CAGR of 3.7% over the forecast period, due to increasing prevalence of infectious diseases.
North America region is expected to dominate the global infectious disease therapeutics market owing to growing research activities for development of novel drug molecules in countries like US and Canada. Asia Pacific region is anticipated to exhibit fastest growth rate during the forecast period due to rising healthcare infrastructural development and increasing spending on pharmaceuticals in populous countries like India and China.
Key players operating in the infectious disease therapeutics market include Novartis International AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, F. Hoffmann-La Roche AG, BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH.
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it